glp 1 receptor agonists beyond their pancreatic effects glp-1_ra_pharmacology [TUSOM The effect of GLP-1R agonists

1 There are four FDA-approved single-entity DPP-4 inhibitors: sitagliptin (the first agent

If additional glycemic control is needed, the dose can be increased in 2.5-mg increments every 4 weeks to a maximum of 15 mg once weekly

3 If A1C goals are not achieved after 3 months of dual therapy, triple therapy is subsequently recommended

These improvements in healthcare infrastructure increase the availability and affordability of insulin and GLP-1 receptor agonists, hence supporting market expansion

They inhibit an enzyme called DPP-IV, which can cause the body to function differently, potentially affecting how tumors develop and spread

Vascular Health and Risk Management , 541-548